Rapid Micro Biosystems (NASDAQ:RPID – Get Free Report) announced its quarterly earnings results on Monday. The company reported ($0.22) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.02), Zacks reports. Rapid Micro Biosystems had a negative net margin of 145.56% and a negative return on equity of 177.04%.
Rapid Micro Biosystems Price Performance
Shares of Rapid Micro Biosystems stock traded up $0.08 during trading on Monday, reaching $0.73. The company’s stock had a trading volume of 2,626,310 shares, compared to its average volume of 230,674. The stock has a 50-day moving average price of $0.92 and a two-hundred day moving average price of $2.08. The stock has a market capitalization of $36.82 million, a P/E ratio of -0.66 and a beta of 1.52. The company has a current ratio of 2.55, a quick ratio of 1.51 and a debt-to-equity ratio of 1.08. Rapid Micro Biosystems has a one year low of $0.58 and a one year high of $4.94.
Wall Street Analyst Weigh In
A number of research analysts have issued reports on the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Rapid Micro Biosystems in a report on Thursday, October 15th. Roth Capital initiated coverage on shares of Rapid Micro Biosystems in a report on Tuesday, September 29th. They set a “buy” rating and a $3.00 price target for the company. One equities research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $5.00.
Check Out Our Latest Report on Rapid Micro Biosystems
About Rapid Micro Biosystems
Rapid Micro Biosystems develops automated microbial detection systems for pharmaceutical, biotechnology and other life sciences manufacturers. Its products are designed to support quality-control testing by identifying and measuring microbial growth in manufacturing environments and products. The company’s Growth Direct platform combines laboratory instruments, consumables and software to automate microbial testing. Its applications include sterility testing, bioburden testing and environmental monitoring, helping manufacturers assess contamination during production.
Featured Articles
- Five stocks we like better than Rapid Micro Biosystems
- Sandisk’s Sell-Off May Be Losing Steam, But the Biggest Risk Still Looms
- Meta’s Access to Capital Remains Strong, But Borrowing Is Becoming More Expensive
- 3 Large-Cap Stocks Are Outperforming the S&P 500 Without AI Hype
- Fossil Just Turned a Profit—Can Its Comeback Survive the Holidays?
Receive News & Ratings for Rapid Micro Biosystems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rapid Micro Biosystems and related companies with MarketBeat.com's FREE daily email newsletter.
